GSK (GSK)

Sector:

Pharma and Biotech

Index:

FTSE 100

1,766.50p
   
  • Change Today:
      36.50p
  • 52 Week High: 1,812.50p
  • 52 Week Low: 1,316.00p
  • Currency: UK Pounds
  • Shares Issued: 4,144.94m
  • Volume: 17,477,210
  • Market Cap: £73,220m
  • RiskGrade: 129

ShareCast News

GSK sales top forecasts 27-Apr-2022 ShareCast
US FDA accepts GSK application for kidney diseas... 19-Apr-2022 ShareCast
GSK agrees to buy Sierra Oncology for $1.9bn 13-Apr-2022 ShareCast
GSK's Cabenuva receives approved label update fr... 24-Mar-2022 ShareCast
EU accepts GSK marketing application for kidney ... 01-Mar-2022 ShareCast
GSK to spin off consumer healthcare unit in July 28-Feb-2022 ShareCast
Glaxo halts trial of respiratory virus maternal ... 28-Feb-2022 ShareCast
GSK and Sanofi seek approval for Covid-19 jab 23-Feb-2022 ShareCast
Glaxo pauses enrolment and vaccination in RSV va... 18-Feb-2022 ShareCast
Director dealings: GSK execs sell shares for tax... 17-Feb-2022 ShareCast
Glaxo's Benlysta lupus treatment approved in Chi... 10-Feb-2022 ShareCast
GSK Covid sales soar but sees slowdown next year 09-Feb-2022 ShareCast
Wednesday preview: Fedspeak, GSK in the spotlight 08-Feb-2022 ShareCast
Glaxo's ViiV Healthcare settles patent row with ... 02-Feb-2022 ShareCast
Glaxo's ViiV Healthcare gets FDA approval for HI... 01-Feb-2022 ShareCast
Unilever said to be planning layoffs after activ... 25-Jan-2022 ShareCast
Unilever won't lift £50bn offer for GSK consumer... 19-Jan-2022 ShareCast
GSK chief science officer leaves to join US star... 19-Jan-2022 ShareCast
Unilever says GSK consumer arm 'strategic fit', ... 17-Jan-2022 ShareCast
BoA stays 'neutral' on Unilever, says upside and... 17-Jan-2022 ShareCast
GlaxoSmithKline's ViiV Healthcare receives FDA a... 21-Dec-2021 ShareCast
Glaxo appoints ex-Tesco boss as chair of new con... 20-Dec-2021 ShareCast
GlaxoSmithKline Covid treatment approved for use... 17-Dec-2021 ShareCast
GSK-Sanofi Covid jab shows 'strong' immune respo... 15-Dec-2021 ShareCast
Medicago and GSK's Covid-19 vaccine shows 75.3% ... 07-Dec-2021 ShareCast
GSK-Vir drug works against all Omicron variants ... 07-Dec-2021 ShareCast
GSK says its Covid-19 treatment works on Omicron 02-Dec-2021 ShareCast
Glaxo poaches new head of vaccines Phil Dormitze... 30-Nov-2021 ShareCast
US secures $1bn of GSK-Vir Covid-19 treatment - ... 17-Nov-2021 ShareCast
EU approves Glaxo's Nucala treatment 17-Nov-2021 ShareCast
GlaxoSmithKline denies interest in Aurinia 01-Nov-2021 ShareCast
Sunday newspaper round-up: Heathrow, GSK, Roll-R... 31-Oct-2021 ShareCast
Glaxo upgrades FY EPS guidance after strong Q3 27-Oct-2021 ShareCast
Wednesday preview: Autumn Budget, GSK in focus 26-Oct-2021 ShareCast
Berenberg says GSK 'undervalued' but pipeline un... 18-Oct-2021 ShareCast
Glaxo's consumer arm drawing interest from priva... 12-Oct-2021 ShareCast
Glaxo unveils plans for £120m consumer healhcare... 11-Oct-2021 ShareCast
GSK, SK Bioscience to start Phase 3 Covid vaccin... 31-Aug-2021 ShareCast
Wednesday broker round-up 18-Aug-2021 ShareCast
Tuesday broker round-up 17-Aug-2021 ShareCast
Sunday newspaper round-up: Meggitt, GlaxoSmithKl... 15-Aug-2021 ShareCast
GlaxoSmithKline Q2 profits, revenue jump 28-Jul-2021 ShareCast
GSK and Vir Biotechnology to supply EU with Cov... 28-Jul-2021 ShareCast
GSK appoints McNamara as CEO designate of consum... 22-Jul-2021 ShareCast
GSK announces positive results for treatment of ... 16-Jul-2021 ShareCast
Wednesday broker round-up 07-Jul-2021 ShareCast
Elliott calls for leadership review at GSK 01-Jul-2021 ShareCast
Thursday broker round-up 24-Jun-2021 ShareCast
Deutsche upgrades GSK after strategy day 24-Jun-2021 ShareCast
GSK sets out ten-year vision, targets sales of £... 23-Jun-2021 ShareCast

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

GSK Market Data

Currency UK Pounds
Share Price 1,766.50p
Change Today 36.50p
% Change 2.11 %
52 Week High 1,812.50p
52 Week Low 1,316.00p
Volume 17,477,210
Shares Issued 4,144.94m
Market Cap £73,220m
RiskGrade 129

GSK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
60.13% below the market average60.13% below the market average60.13% below the market average60.13% below the market average60.13% below the market average
17.65% above the sector average17.65% above the sector average17.65% above the sector average17.65% above the sector average17.65% above the sector average
Price Trend
51.02% above the market average51.02% above the market average51.02% above the market average51.02% above the market average51.02% above the market average
66.67% above the sector average66.67% above the sector average66.67% above the sector average66.67% above the sector average66.67% above the sector average
Income
7.92% above the market average7.92% above the market average7.92% above the market average7.92% above the market average7.92% above the market average
14.29% above the sector average14.29% above the sector average14.29% above the sector average14.29% above the sector average14.29% above the sector average
Growth
20.6% below the market average20.6% below the market average20.6% below the market average20.6% below the market average20.6% below the market average
42.86% above the sector average42.86% above the sector average42.86% above the sector average42.86% above the sector average42.86% above the sector average

What The Brokers Say

Strong Buy 8
Buy 5
Neutral 9
Sell 2
Strong Sell 0
Total 24
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

GSK Dividends

  Latest Previous
  Q1 Q4
Ex-Div 16-May-24 22-Feb-24
Paid 11-Jul-24 11-Apr-24
Amount 15.00p 16.00p

Trades for 31-May-2024

Time Volume / Share Price
16:51 4,960 @ 1,766.50p
16:51 4,960 @ 1,766.50p
16:47 5,664 @ 1,762.12p
16:42 14,195 @ 1,766.50p
16:42 30,128 @ 1,766.50p

GSK Key Personnel

CEO Emma Walmsley

Top of Page